X
[{"orgOrder":0,"company":"Organovo Holdings","sponsor":"Mutabilis","pharmaFlowCategory":"D","amount":"$11.9 million","upfrontCash":"Undisclosed","newsHeadline":"Novo Holdings REPAIR Impact Fund Invests USD 12 Million in Mutabilis and IBT Vaccines and Provides Strategic Update","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Discovery","country":"U.S.A","productType":"Undisclosed","productStatus":"New Molecular Entity","date":"January 2020","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Discovery"},{"orgOrder":0,"company":"Organovo Holdings","sponsor":"Tarveda Therapeutics","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Tarveda Therapeutics Provides Update on Proposed Merger with Organovo","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"U.S.A","productType":"Small molecule","productStatus":"New Molecular Entity","date":"April 2020","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II"},{"orgOrder":0,"company":"Organovo Holdings","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Organovo Advances Clinical Timelines for FXR314 and Provides Updates on NASH Phase 2 Data","therapeuticArea":"Gastroenterology","highestDevelopmentStatus":"Phase I","country":"U.S.A","productType":"Small molecule","productStatus":"New Molecular Entity","date":"August 2023","url1":"","url2":"","graph1":"Gastroenterology","graph2":"Phase I"},{"orgOrder":0,"company":"Organovo Holdings","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Organovo Announces Positive Phase 2 Results for FXR314 in Metabolic Dysfunction-Associated Steatohepatitis (MASH) Showing Both Reduction in Liver Fat Content and Strong Safety and Tolerability Compared to Placebo","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","highestDevelopmentStatus":"Phase II","country":"U.S.A","productType":"Small molecule","productStatus":"New Molecular Entity","date":"April 2024","url1":"","url2":"","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Phase II"},{"orgOrder":0,"company":"Organovo Holdings","sponsor":"JonesTrading Institutional Services","pharmaFlowCategory":"D","amount":"$5.2 million","upfrontCash":"Undisclosed","newsHeadline":"Organovo Holdings, Inc. Announces Pricing of $5.25 Million Public Offering","therapeuticArea":"Gastroenterology","highestDevelopmentStatus":"Phase I","country":"U.S.A","productType":"Small molecule","productStatus":"New Molecular Entity","date":"May 2024","url1":"","url2":"","graph1":"Gastroenterology","graph2":"Phase I"}]
Find Clinical Drug Pipeline Developments & Deals by Organovo Holdings
Filters
Companies By Therapeutic Area
Details:
The net proceeds will be used to advance company's pipeline including its lead molecule, FXR314, is on the path for Phase 2 investigation in inflammatory bowel disease and has applications in metabolic liver disease and oncology.
Lead Product(s):
FXR314
Therapeutic Area: Gastroenterology
Product Name: FXR314
Highest Development Status: Phase I
Product Type: Small molecule
Partner/Sponsor/Collaborator:
JonesTrading Institutional Services
Deal Size: $5.2 million
Upfront Cash: Undisclosed
Deal Type: Public Offering
May 08, 2024
Details:
The company’s lead molecule, FXR314, the non-steroidal, non-bile acid FXR agonist, is being developed for the treatment of metabolic function-associated steatohepatitis (MASH).
Lead Product(s):
FXR314
Therapeutic Area: Hepatology (Liver, Pancreatic, Gall Bladder)
Product Name: FXR314
Highest Development Status: Phase II
Product Type: Small molecule
Partner/Sponsor/Collaborator:
Not Applicable
Deal Size: Not Applicable
Upfront Cash: Not Applicable
Deal Type: Not Applicable
April 15, 2024
Details:
FXR314, an FXR agonist, has completed initial clinical trials. FXR314 is a drug with safety and tolerability after daily oral dosing in Phase 1 and Phase 2 trials. Further, FXR314 has FDA clinical trial authorization for a Phase 2 trial in ulcerative colitis.
Lead Product(s):
FXR314
Therapeutic Area: Gastroenterology
Product Name: FXR314
Highest Development Status: Phase I
Product Type: Small molecule
Partner/Sponsor/Collaborator:
Not Applicable
Deal Size: Not Applicable
Upfront Cash: Not Applicable
Deal Type: Not Applicable
August 23, 2023
Details:
Unanticipated late opposition by major Organovo stockholder results in termination of proposed merger agreement.
Lead Product(s):
Locnartecan
Therapeutic Area: Oncology
Product Name: Undisclosed
Highest Development Status: Phase I/ Phase II
Product Type: Small molecule
Recipient:
Tarveda Therapeutics
Deal Size: Undisclosed
Upfront Cash: Undisclosed
Deal Type: Termination
April 07, 2020
Details:
This investment will allow the Mutabilis to accelerate its 2G-Dabocins program, a wide spectrum Gram-negative anti-infective agent, which is currently undergoing lead optimization.
Lead Product(s):
2G-Dabocins
Therapeutic Area: Infections and Infectious Diseases
Product Name: Undisclosed
Highest Development Status: Discovery
Product Type: Undisclosed
Recipient:
Mutabilis
Deal Size: $11.9 million
Upfront Cash: Undisclosed
Deal Type: Financing
January 06, 2020